Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. Common Stock (RAPP) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · RAPP · as of Jun 8, 2026
Activity summary
Buy transactions
4
P-Purchase only
Sell transactions
58
12 Months
Buy/Sell ratio
0.07
Buy/Sell (by trades)
Overall sentiment
Rapport Therapeutics, Inc. Common Stock insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
RAPP insider buying and selling by quarter
RAPP insider selling · RAPP insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · RAPP ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
RAPP executive sell shares · RAPP board member insider trading · RAPP insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 26, 2026 | Third Rock Ventures V, L.P. 10 percent owner | Sale | 18,572 | $744K | Form 4 |
| May 11, 2026 | Third Rock Ventures V, L.P. 10 percent owner | Sale | 133,618 | $5.38M⚡ | Form 4 |
| May 7, 2026 | Third Rock Ventures V, L.P. 10 percent owner | Sale | 271,495 | $10.89M⚡ | Form 4 |
| May 8, 2026 | Third Rock Ventures V, L.P. 10 percent owner | Sale | 5,018 | $202K | Form 4 |
| Apr 17, 2026 | Third Rock Ventures V, L.P. 10 percent owner | Sale | 426,005 | $17.18M⚡ | Form 4 |
| Apr 17, 2026 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | 20,225 | $809K | Form 4 |
| Apr 10, 2026 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | 500 | $17K | Form 4 |
| Apr 13, 2026 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | 9,165 | $321K | Form 4 |
| Apr 14, 2026 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | 10,200 | $358K | Form 4 |
| Apr 8, 2026 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | 360 | $13K | Form 4 |
| Mar 30, 2026 | Gault Cheryl COO | Sale | 7,161 | $201K | Form 4 |
| Mar 30, 2026 | Gault Cheryl COO | Sale | 2,839 | $81K | Form 4 |
| Mar 25, 2026 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | 10,115 | $303K | Form 4 |
| Mar 5, 2026 | Gault Cheryl COO | Sale | 2,014 | $58K | Form 4 |
| Feb 18, 2026 | Ceesay Abraham CEO · Director | Sale | 3,552 | $103K | Form 4 |
| Feb 18, 2026 | Ceesay Abraham CEO · Director | Sale | 2,281 | $68K | Form 4 |
| Feb 18, 2026 | Ceesay Abraham CEO · Director | Sale | 2,983 | $87K | Form 4 |
| Feb 18, 2026 | Ceesay Abraham CEO · Director | Sale | 2,100 | $63K | Form 4 |
| Feb 17, 2026 | Bredt David Chief Scientific Officer | Sale | 900 | $25K | Form 4 |
| Feb 19, 2026 | Bredt David Chief Scientific Officer | Option | 6,000 | $11K | Form 4 |
| Feb 17, 2026 | Bredt David Chief Scientific Officer | Sale | 5,400 | $156K | Form 4 |
| Feb 17, 2026 | Bredt David Chief Scientific Officer | Sale | 2,200 | $65K | Form 4 |
| Jan 20, 2026 | Ceesay Abraham CEO · Director | Sale | 5,833 | $152K | Form 4 |
| Jan 20, 2026 | Ceesay Abraham CEO · Director | Sale | 5,083 | $133K | Form 4 |
| Jan 15, 2026 | Bredt David Chief Scientific Officer | Sale | 8,300 | $223K | Form 4 |
Third Rock Ventures V, L.P.
10 percent owner
Date
May 26
Shares
18,572
Price
$40.05
Value
$744K
Third Rock Ventures V, L.P.
10 percent owner
Date
May 11
Shares
133,618
Price
$40.24
Value
$5.38M ⚡
Third Rock Ventures V, L.P.
10 percent owner
Date
May 7
Shares
271,495
Price
$40.12
Value
$10.89M ⚡
Third Rock Ventures V, L.P.
10 percent owner
Date
May 8
Shares
5,018
Price
$40.31
Value
$202K
Third Rock Ventures V, L.P.
10 percent owner
Date
Apr 17
Shares
426,005
Price
$40.32
Value
$17.18M ⚡
Yeleswaram Krishnaswamy
Chief Development Officer
Date
Apr 17
Shares
20,225
Price
$39.99
Value
$809K
Yeleswaram Krishnaswamy
Chief Development Officer
Date
Apr 10
Shares
500
Price
$34.98
Value
$17K
Yeleswaram Krishnaswamy
Chief Development Officer
Date
Apr 13
Shares
9,165
Price
$34.97
Value
$321K
Yeleswaram Krishnaswamy
Chief Development Officer
Date
Apr 14
Shares
10,200
Price
$35.08
Value
$358K
Yeleswaram Krishnaswamy
Chief Development Officer
Date
Apr 8
Shares
360
Price
$34.90
Value
$13K
Yeleswaram Krishnaswamy
Chief Development Officer
Date
Mar 25
Shares
10,115
Price
$29.99
Value
$303K
Bredt David
Chief Scientific Officer
Date
Feb 17
Shares
900
Price
$28.02
Value
$25K
Bredt David
Chief Scientific Officer
Date
Feb 19
Shares
6,000
Price
$1.80
Value
$11K
Bredt David
Chief Scientific Officer
Date
Feb 17
Shares
5,400
Price
$28.95
Value
$156K
Bredt David
Chief Scientific Officer
Date
Feb 17
Shares
2,200
Price
$29.59
Value
$65K
Bredt David
Chief Scientific Officer
Date
Jan 15
Shares
8,300
Price
$26.83
Value
$223K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About RAPP insider trading
RAPP insider trades
Rapport Therapeutics, Inc. Common Stock (RAPP) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Ceesay Abraham (CEO · Director), Bredt David (Chief Scientific Officer), Yeleswaram Krishnaswamy (Chief Development Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. RAPP insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Rapport Therapeutics, Inc. Common Stock's institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
RAPP insider trading · 5 questionsThe insiders of Rapport Therapeutics, Inc. Common Stock (RAPP) include executives and directors such as Ceesay Abraham (CEO · Director), Bredt David (Chief Scientific Officer), Yeleswaram Krishnaswamy (Chief Development Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026